来自随机临床试验的信号预测flupirtine的肝毒性:系统审查
Mahir Fidahic1, Emilija Lozo Vukovac2, Ewa Balkowiec-Iskra3,4
1Agency for Quality and Accreditation in Healthcare in the FBIH, Sarajevo, Bosnia and Herzegovina.
European journal of clinical pharmacology
|April 23, 2025
概括
这一系统性审查没有发现在已发表的随机对照试验 (RCT) 中存在严重的flupirtine肝毒性的证据. 然而,肝功能数据有限,质疑可靠性RCT评估flupirtine相关的肝损伤.
科学领域:
- 药物监督 药物监督 药物监督
- 临床试验分析
- 药品安全 药品安全
背景情况:
- 弗卢皮尔丁是一种非止痛药,引起了人们对潜在肝脏毒性的担忧.
- 对临床试验的系统审查对于评估药物安全性概况至关重要.
研究的目的:
- 系统地审查flupirtine的随机对照试验 (RCT).
- 为了确定与flupirtine相关的严重肝毒性生物化学或临床指标.
主要方法:
- 对评估含有flupirtine的药物的RCT进行系统审查.
- 在Embase,MEDLINE和CENTRAL数据库中进行的搜索截至2023年8月14日.
- 使用Cochrane的2011年RoB工具评估偏差风险;因异质性而排除元分析.
主要成果:
- 包括35项试验 (1408名参与者);只有5项报告的肝功能测试 (LFT).
- 四项试验显示过渡性,无症状的LFT异常;一项试验提前结束.
- 大多数试验具有不清楚的偏差风险;关于flupirtine戒断的数据有限.
结论:
- 已发表的RCT缺乏足够的数据来证实或反驳flupirtine引起的严重肝毒性.
- 在RCT中对LFT的报告有限,这破坏了评估flupirtine肝脏安全性的可靠性.
- 需要进一步调查flupirtine的肝毒性潜力.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...


